## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### **Listing of Claims:**

# 1. (Original) A nucleotide derivative of formula 1

wherein

 $R^1$  is selected from the group consisting of a straight-chain or branched, saturated or unsaturated alkyl chain having 1-20 carbon atoms, which is unsubstituted or substituted at least once by halogen,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  alkylsulfinyl or  $C_1$ - $C_6$  alkylsulfonyl groups;

 $R^2$  is selected from the group consisting of hydrogen, a straight-chain or branched, saturated or unsaturated alkyl chain having 1-20 carbon atoms, which is unsubstituted or substituted at least once by halogen,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  alkylmercapto,  $C_1$ - $C_6$  alkoxycarbonyl or  $C_1$ - $C_6$  alkylsulfonyl groups;

R<sup>3</sup> is amino or OR<sup>4</sup>, wherein R<sup>4</sup> is C<sub>1</sub>-C<sub>8</sub> alkyl;

X is selected from the group consisting of a sulfur atom, a sulfinyl group and a sulfonyl group;

## Y is oxygen;

whereby when R³ is amino, said amino group may be unsubstituted or substituted by a known amino protecting group, their tautomers, their optically active forms and racemic mixtures, and their physiologically acceptable salts of inorganic and organic acids or bases.

- (Original) The nucleotide derivative according to claim 1, wherein R<sup>1</sup> is a straight-chain C<sub>8</sub>-C15 alkyl group, which is unsubstituted or substituted by a C<sub>1</sub>-C<sub>6</sub> alkoxy or a C<sub>1</sub>-C<sub>6</sub> alkylmercapto group.
- 3. (Original) The nucleotide derivative according to claim 1, wherein  $R^2$  represents a straight-chain C8-C<sub>15</sub> alkyl group, which is unsubstituted or substituted by a C<sub>1</sub>-C<sub>6</sub> alkoxy or a C<sub>1</sub>-C<sub>6</sub> alkylmercapto group.
- 4. (Currently Amended) The nucleotide derivative according to claims 1 to 3 1, wherein R³ is OCH₃.
- 5. (Currently Amended) The nucleotide derivative according the claims 1-4 to claim 1, wherein the compound is:

wherein X is sulfur, sulfinyl or sulfonyl.

- 6. (Currently Amended) The nucleotide derivative according to claims 1 to 3  $\underline{1}$ , wherein  $R^3$  is  $NH_2$ .
- (Currently Amended) The nucleotide derivative according to claims 1 to 3 or 6
  wherein the compound is:

$$\begin{array}{c} C_{12}H_{25} - X \\ C_{10}H_{21} - O \end{array} \begin{array}{c} O \\ O \\ O \end{array} \begin{array}{c} N \\ N \\ O \end{array} \begin{array}{c} N \\ N \\ O \end{array} \begin{array}{c} C_{10}H_{21} - O \\ O \\ O \\ O \end{array} \begin{array}{c} N \\ N \\ N \\ O \end{array} \begin{array}{c} N \\ N \\ O \end{array} \begin{array}{c} N \\ N \\ N \\ O \end{array} \begin{array}{c} N \\ N \\ N \\ O \end{array} \begin{array}{c} N \\ N \\ N \\ O \end{array} \begin{array}{c} N \\ N \\ N \\ O \end{array} \begin{array}{c} N \\ N \\ N \\ O \end{array} \begin{array}{c} N \\ N \\ N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \end{array} \begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} N \\$$

wherein X is sulfur, sulfinyl or sulfonyl.

- 8. (Currently Amended) A pharmaceutical composition comprising at least one compound according to claims 1-7 1 in combination with a pharmaceutically acceptable adjuvant or vehicle.
- 9. (Currently Amended) A method for treating malignant tumors comprising administering to a patient in need of such treatment an amount of a compound according to claims 1 7 1 effective to treat said tumors.
- 10. (Original) The method according to claim 9, wherein said tumor is selected from the group consisting of carcinomas, sarcomas or leukemias.
- 11. (Original) A method for treating malignant tumors comprising administering to a patient in need of such treatment an amount of the composition according to claim 8 effective to treat said tumors in fixed or free combination with other anticancer agents.

# 12. (Original) A method of synthesis of compounds of the formula la:

wherein R  $^1$  is is a straight-chain o r b ranched, saturated o r u nsaturated alkyl residue having 1-20 carbon atoms, optionally mono- or polysubstituted by halogen,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  alkylsulfinyl or  $C_1$ - $C_6$  alkylsulfonyl groups;

R<sup>2</sup> is hydrogen, a straight-chain or branched, saturated or unsaturated alkyl chain having 1-20 carbon atoms, optionally mono- or polysubstituted by halogen, C <sub>1</sub>-C<sub>6</sub> a ikoxy, C 1-C6 alkylmercapto, C <sub>1</sub>-C<sub>6</sub> a lkoxycarbonyl or C <sub>1</sub>-C<sub>6</sub> alkylsulfonyl groups;

X is selected from the group consisting of a sulfur atom, a sulfinyl group and a sulfonyl group;

Y is oxygen;

comprising:

(a) reacting 2,6-dichioroadenine with an arabinofuranosyl derivative of the formula:

wherein R<sup>5</sup> is bromo or chioro and R<sup>6</sup> and R<sup>7</sup> are protecting groups, in the presence of a hindered potassium base and a solvent to form the dichioropurine nucleoside derivative:

(b) subjecting said dichloro purine nucleoside derivative to conditions to provide for deprotection and an aromatic nucleophilic substitution reaction to provide the 6-alkoxy-2-chloro purine nucleoside derivative of general formula IIIb:

wherein R4 is C1-C8 alkyl;

(c) reacting said 6-alkoxy-2-chioro purine nucleoside derivative with an activated form of the compound:

in an inert solvent to provide the conjugated 6-alkoxy-2-chloro purine nucleotide derivative of general formula lb:

(d) subjecting said conjugated 6-alkoxy-2-chloro purine nucleotide derivative to conditions that provide for aminolysis to prepare the conjugated 2-chioroadenine derivative:

- (Original) The method of claim 12 wherein, said hindered potassium base is potassium t-butoxide or potassium f-amylate.
- 14. (Original) The method of claim 12, wherein said solvent for reacting said 2,6-dichloroadenine and said arabinofuranosyl derivative is a mixture of acetonitrile, f-butanol and 1,2-dichloroethane.
- 15. (Original) The method of claim 12, wherein R<sup>4</sup> is methyl.

- 16. (Original) The method of claim 12, wherein R⁵ is bromo.
- 17. (Original) The method of claim 12, wherein R<sup>6</sup> and R<sup>7</sup> are independently acetyl or benzoyl.
- 18. (Original) The method of claim 12, wherein  $R^1$  and  $R^2$  are individually a straight-chain  $C_8$ - $C_{15}$  alkyl group, which is unsubstituted or substituted by a  $C_1$ - $C_6$  alkoxy or a  $C_1$ - $C_6$  alkylmercapto group.
- 19. (Original) The method of claim 12, wherein R<sup>1</sup> is C<sub>12</sub>H<sub>25</sub> and R<sup>2</sup> is C<sub>10</sub>H<sub>21</sub>.